Engineered Extracellular Vesicle-Based Therapies for Valvular Heart Disease

Area of Science:

• Cardiovascular Research
• Nanomedicine
• Regenerative Medicine

Background:

• Valvular heart disease, particularly calcific aortic stenosis (CAS), is a major health concern in aging populations.
• Current treatments like valve replacement have limitations in long-term durability.
• Novel strategies are needed to halt or reverse CAS progression.

Purpose of the Study:

• To explore the potential of extracellular vesicles (EVs) as nanocarriers for delivering therapeutic payloads to diseased aortic valves.
• To investigate the use of engineered EVs loaded with specific transcription factors to reduce inflammation and promote calcified tissue resorption.

Main Methods:

• Engineered EVs were loaded with reprogramming myeloid transcription factors, CEBPA and Spi1.
• The ability of these EVs to deliver genetic material and induce cell transdifferentiation was evaluated in patient-derived aortic valve tissue.
• In vitro and ex vivo models were used to assess the induction of macrophage-like cells from endothelial cells.

Main Results:

• Engineered EVs loaded with CEBPA and Spi1 were successfully derived from human dermal fibroblasts.
• These EVs effectively transfected aortic valve cells, inducing the transdifferentiation of endothelial cells into anti-inflammatory macrophage-like cells.
• Successful transdifferentiation was observed both in vitro and ex vivo.

Conclusions:

• Engineered EVs show potential as a next-generation nanocarrier for targeting aberrant calcifications in heart valves.
• This approach may offer a novel therapeutic option for high-risk patients unsuitable for valve replacement surgery.